FDA Clears First Treatment for Rare MCT8 Deficiency
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Emcitate, or tiratricol, as the first therapy for peripheral thyrotoxicosis in patients with MCT8 deficiency, establishing a treatment option for …
FDA Clears First Treatment for Rare MCT8 Deficiency Read More